Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matt Kalaycio

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|February 1, 2020
Distinctive and common features of moderate aplastic anaemiaBhumika J Patel, Shimoli V Barot, Teodora Kuzmanovic, et al.
Blood Cancer Journal|January 12, 2018
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, et al.
Leukemia & Lymphoma|July 12, 2017
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete responseCaner Saygin, Nikolaos Papadantonakis, Ryan D Cassaday, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
British Journal of Haematology|October 14, 2009
Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemiaShubham Pant, Mehdi Hamadani, Anthony J Dodds, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Journal of the National Cancer Institute|March 1, 2014
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiationSudipto Mukherjee, Chandana A Reddy, Jay P Ciezki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemiaEric J Feldman, Joseph Brandwein, Richard Stone, et al.
Leukemia & Lymphoma|January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trialClemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
British Journal of Haematology|January 21, 2020
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantationHassan Awada, Reda Z Mahfouz, Jibran Durrani, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|February 1, 2020
Distinctive and common features of moderate aplastic anaemiaBhumika J Patel, Shimoli V Barot, Teodora Kuzmanovic, et al.
Blood Cancer Journal|January 12, 2018
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, et al.
Leukemia & Lymphoma|July 12, 2017
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete responseCaner Saygin, Nikolaos Papadantonakis, Ryan D Cassaday, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerRemco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, et al.
British Journal of Haematology|October 14, 2009
Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemiaShubham Pant, Mehdi Hamadani, Anthony J Dodds, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Journal of the National Cancer Institute|March 1, 2014
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiationSudipto Mukherjee, Chandana A Reddy, Jay P Ciezki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemiaEric J Feldman, Joseph Brandwein, Richard Stone, et al.
Leukemia & Lymphoma|January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trialClemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
British Journal of Haematology|January 21, 2020
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantationHassan Awada, Reda Z Mahfouz, Jibran Durrani, et al.
Pageof 13